Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Biorxiv : the Preprint Server for Biology|February 19, 2024
Inhibition of ULK1/2 and KRAS G12C controls tumor growth in preclinical models of lung cancerPhaedra C Ghazi, Kayla T O'Toole, Sanjana Srinivas Boggaram, et al.
Cancer Research|April 21, 2011
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profileChristopher A Eide, Lauren T Adrian, Jeffrey W Tyner, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2022
Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)Timothy M Caldwell, Yu Mi Ahn, Stacie L Bulfer, et al.
Molecular Cancer Therapeutics|August 26, 2021
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by MacrophagesBryan D Smith, Michael D Kaufman, Scott C Wise, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2022
Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitorsTimothy M Caldwell, Michael D Kaufman, Scott C Wise, et al.
Haematologica|December 9, 2016
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemiaJorge Cortes, Moshe Talpaz, Hedy P Smith, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2010
Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge regionYu Mi Ahn, Michael Clare, Carol L Ensinger, et al.
Molecular Cancer Therapeutics|August 26, 2017
The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine TumorsAllison S Harney, George S Karagiannis, Jeanine Pignatelli, et al.
Molecular Oncology|March 20, 2024
Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacyYasmin Yu, Madhumita Bogdan, Muhammad Zaeem Noman, et al.
Molecular Cancer Therapeutics|August 20, 2015
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2Bryan D Smith, Michael D Kaufman, Cynthia B Leary, et al.
Pageof 3